NK cells also participate in the clinical benefit of PD-1/PD-L1 antibody therapy, and NK cells also have greater off-the-shelf utility and are safer than other cell-therapies (e.g. CAR-T), as they cause fewer immune-related adverse events, this study was aimed to evaluate the efficacy and safety of autologous NK cells combined with PD-1 antibody for advanced driven mutation negative NSCLC as a second-line therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.